Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06551844 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adaptive Dengue Antiviral Platform Trial

Study acronym: ADAPT
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 2 of 9 entries
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
    • Start date changed from estimate of Sep 1, 2025 to Apr 20, 2026
    • Study sites: 1 to 2
    • Interventions: Molnupiravir 400 mg (Drug), VIS513 (a monoclonal antibody) (Drug) to Molnupiravir 400 mg (Drug), Remdesivir 100mg (Drug), VIS513 (a monoclonal antibody) (Drug)
    • Study description expanded, about 14 words
    • Collaborators: 1 to 2
    • Study arms: 3 to 4
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, open-label adaptive platform trial aiming to screen the antiviral effectiveness of the experimental drug(s) in early dengue infection * Primary objectives: * To determine the antiviral effectiveness of the experimental drug(s) in early dengue infection * To assess the safety and tolerability of the experimental drug(s) in dengue patients * Secondary objective: * To assess the effect of the experimental drug(s) in dengue patients on physiological, clinical and virological parameters
Trial Details
NCT Number NCT06551844
Lead Sponsor Oxford University Clinical Research Unit, Vietnam
Collaborators: Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, University Malaya Medical Centre, Malaysia
Conditions
(from sponsor)		 Dengue, Antiviral Drugs
Related terms Dengue
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov